Nancy Lurker - 02 Jul 2025 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Reporting relationship: Director
Issuer ticker: EYPT
Reported as of: 02 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jul 2025, 16:05:58 UTC
Prior SEC filing: 02 Jun 2025
Next SEC filing: 11 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Ron Honig, Attorney-in-Fact

Key filing fact

Nancy Lurker filed Form 4 for EyePoint Pharmaceuticals, Inc. (EYPT) on 02 Jul 2025.

Key facts

This page summarizes Nancy Lurker's Form 4 filing for EyePoint Pharmaceuticals, Inc. (EYPT).
10 reported transactions and 10 derivative rows are listed below.
Accepted by SEC: 02 Jul 2025, 16:05.

Change

Previous filing in this sequence was filed on 02 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001450485 Primary reporting owner

Lurker Nancy

Relationship: Director
Address: C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN
Signature: /s/ Ron Honig, Attorney-in-Fact
Signature date: 02 Jul 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EYPT transaction Derivative

Stock Option (Right to Buy)

Gift

Transaction value: $0
Shares: -31,165
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 02 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 31,165
Exercise price: $13.13
Footnotes: F1, F2

EYPT transaction Derivative

Stock Option (Right to Buy)

Gift

Transaction value: $0
Shares: +31,165
Change %: +17%
Price: $0.000000
Shares after: 213,700
Date: 02 Jul 2025
Ownership: By Family Trust
Underlying class: Common Stock
Underlying amount: 31,165
Exercise price: $13.13
Footnotes: F1, F2, F3

EYPT transaction Derivative

Stock Option (Right to Buy)

Gift

Transaction value: $0
Shares: -55,000
Change %: -58%
Price: $0.000000
Shares after: 40,000
Date: 02 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 55,000
Exercise price: $10.13
Footnotes: F1, F4

EYPT transaction Derivative

Stock Option (Right to Buy)

Gift

Transaction value: $0
Shares: +55,000
Change %: +38%
Price: $0.000000
Shares after: 200,000
Date: 02 Jul 2025
Ownership: By Family Trust
Underlying class: Common Stock
Underlying amount: 55,000
Exercise price: $10.13
Footnotes: F1, F3, F4

EYPT transaction Derivative

Stock Option (Right to Buy)

Gift

Transaction value: $0
Shares: -103,308
Change %: -37%
Price: $0.000000
Shares after: 178,442
Date: 02 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 103,308
Exercise price: $3.26
Footnotes: F1, F5

EYPT transaction Derivative

Stock Option (Right to Buy)

Gift

Transaction value: $0
Shares: +103,308
Change %: +61%
Price: $0.000000
Shares after: 272,358
Date: 02 Jul 2025
Ownership: By Family Trust
Underlying class: Common Stock
Underlying amount: 103,308
Exercise price: $3.26
Footnotes: F1, F3, F5

EYPT transaction Derivative

Stock Option (Right to Buy)

Gift

Transaction value: $0
Shares: -15,278
Change %: -31%
Price: $0.000000
Shares after: 34,722
Date: 02 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,278
Exercise price: $9.11
Footnotes: F1, F6

EYPT transaction Derivative

Stock Option (Right to Buy)

Gift

Transaction value: $0
Shares: +15,278
Change %: +92%
Price: $0.000000
Shares after: 31,944
Date: 02 Jul 2025
Ownership: By Family Trust
Underlying class: Common Stock
Underlying amount: 15,278
Exercise price: $9.11
Footnotes: F1, F3, F6

EYPT transaction Derivative

Stock Option (Right to Buy)

Gift

Transaction value: $0
Shares: -27,270
Change %: -35%
Price: $0.000000
Shares after: 49,730
Date: 02 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,270
Exercise price: $20.40
Footnotes: F1, F7

EYPT transaction Derivative

Stock Option (Right to Buy)

Gift

Transaction value: $0
Shares: +27,270
Change %
Price: $0.000000
Shares after: 27,270
Date: 02 Jul 2025
Ownership: By Family Trust
Underlying class: Common Stock
Underlying amount: 27,270
Exercise price: $20.40
Footnotes: F1, F3, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust").

Footnote F2

The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full.

Footnote F3

These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Footnote F4

The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026.

Footnote F5

The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 6, 2027.

Footnote F6

The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until July 10, 2027.

Footnote F7

The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 5, 2028.